Early CD4+ T cell recovery in human immunodeficiency virus - Infected patients receiving effective therapy is related to a down-regulation of apoptosis and not to proliferation

Journal of Infectious Diseases

Volumn 185, Issue 4, 2002, Pages 463-470

  Roger, Pierre Marie ^a   Breittmayer, Jean Philippe ^b   Durant, Jacques ^a   Sanderson, Frédéric ^c   Ceppi, Carole ^d   Brignone, Christelle ^b   Cua, Eric ^c   Clevenbergh, Philippe ^a   Fuzibet, Jean Gabriel ^c   Pesce, Alain ^d   Bernard, Alain ^b   Dellamonica, Pierre ^a  

^a Hop l'Archet Rte S Antoine G   (France)

^b INSERM   (France)

^c Service de Médecine Interne   (France)

^d CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ANTIVIRAL ACTIVITY; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; VIRUS CELL INTERACTION; VIRUS LOAD;

ADULT; AGED; ANTI-HIV AGENTS; APOPTOSIS; CD4 LYMPHOCYTE COUNT; CELL DIVISION; DOWN-REGULATION; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED;

EID: 0037083249     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/338573     Document Type: Article

References (40)

1. Epidemiology of human immuno-deficiency virus - Associated opportunistic infections in the United States in the era of highly active antiretroviral therapy
2. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic reconstitution after 6 months of highly active antiretroviral therapy
3. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study
4. + T cell counts despite virologic failure of protease inhibitor - Containing antiretroviral combination therapy
5. + T cells from human immunodeficiency virus - Infected individuals
6. Analysis of apoptosis in lymph nodes of HIV-infected persons
7. Fas antigen stimulation induces marked apoptosis of T lymphocytes in human immunodeficiency virus - Infected individuals
8. Programmed cell death in peripheral lymphocytes from HIV-infected persons
9. Apoptosis occurs predominantly in bystander cells and not in productively infected cells of HIV- and SIV-infected lymph nodes
10. + antigen-specific T cells to undergo apoptosis by HIV-infected monocytes
11. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: A composite of redistribution and proliferation
12. Long-term kinetics of T cell production in HIV-infected subjects treated with highly active antiretroviral therapy
13. Factors influencing T-cell turnover in HIV-1 - Seropositive patients
14. Directly measured kinetics of circulating T lymphocytes in normal and HIV-1 - Infected humans
15. High prevalence of thymic tissue in adults with human immunodeficiency virus - 1 infection
16. Changes in thymic function with age and during the treatment of HIV infection
17. Thymic size and lymphocyte restoration in patients with human immunodeficiency virus infection after 48 weeks of zidovudine, lamivudine, and ritonavir therapy
18. + T lymphocytes in HIV-1 infection as measured by Ki-67 antigen
19. HIV protease inhibitors restore impaired T-cell proliferative reconstitution in vivo and in vitro: A viral-suppression - Independent mechanism
20. Initial increase in blood CD4(+) lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues
21. Kinetics of the changes of lymphocyte subsets defined by cytokine production at single cell level during highly active antiretroviral therapy for HIV-1 infection
22. Human immunodeficiency virus type 1 protease inhibitor modulates activation of peripheral blood CD4(+) T cells and decreases their susceptibility to apoptosis in vitro and in vivo
23. Tumor necrosis factor (TNF) system levels in human immunodeficiency virus - Infected patients during highly active antiretroviral therapy: Persistent TNF activation is associated with virologic and immunologic treatment failure
24. + T cell apoptosis in HIV-infected patients
25. Drug-resistance genotyping in HIV-1 therapy: The VIRADAPT randomised controlled trial
26. Apoptosis of immature thymocytes mediated by E2/CD99
27. Impact of highly active anti-retroviral therapy (HAART) on cytokine production and monocyte subsets in HIV-infected patients
28. Assessment of type 1 and type 2 cytokines in HIV type 1 - Infected individuals: Impact of highly active antiretroviral therapy
29. IL-2 rescues in vitro lymphocyte apoptosis in patients with HIV infection
30. Treatment with indinavir, zidovudine and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
31. In vivo analysis of Fas/FasL interactions in HIV-infected patients
32. Spontaneous and anti-Fas - Induced apoptosis in lymphocytes from HIV-infected patients undergoing highly active anti-retroviral therapy
33. High plasma levels of soluble fas in HIV type 1 - Infected subjects are not normalized during highly active antiretroviral therapy
34. Immune reconstitution in HIV infection
35. Persistent viral load in patients on HAART is associated with a higher level of activation-induced apoptosis of CD4(+) T cells
36. HIV induces thymus depletion in vivo
37. HIV-1 - Induced thymocyte depletion is associated with indirect cytopathogenicity and infection of progenitor cells in vivo
38. Mechanisms associated with thymocyte apoptosis induced by simian immunodeficiency virus
39. Early immune reconstitution after potent antiretroviral therapy in HIV-infected children correlates with the increase in thymus volume
40. 6 cells/l